Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Intellinetics Q2 2026 Earnings Call - SaaS Growth Outpaces Declining Services Revenue Amid Leadership Transition
Intellinetics reported a challenging second quarter for 2026, with total revenue dipping 1.6% to $3.9 million as legacy document services and professional services volumes contracted. The drag from lo...
- Total revenue for Q2 2026 decreased 1.6% year-over-year to $3.9 million, reflecting a mix shift away from project-based work.
- SaaS revenue grew 4.2% year-over-year to $1.6 million, with new Payables Automation customers serving as the primary growth driver.
- Professional services revenue fell 5.8% to $1.8 million, representing 45% of total revenue, down from 47% in the prior year period.
- +12 more takeaways
Spire Global Inc Q2 2026 Earnings Call - Core Revenue Accelerates as 85% of Full-Year Guidance Is Contracted
Spire Global delivered a quarter defined by accelerating core revenue growth and de-risking its 2026 outlook. Q2 revenue hit $18 million, marking the strongest core performance since the maritime dive...
- Second-quarter core revenue reached $18 million, up 16% year-over-year and 19% sequentially, representing the strongest core performance since the maritime business divestiture.
- Management reaffirmed full-year 2026 revenue guidance of $75 million to $85 million, implying a significant acceleration in the second half with roughly $41 million to $51 million needed to close the gap.
- Over 85% of the full-year guidance midpoint is now contracted as of late July, up from 76% in May, providing high visibility into H2 execution.
- +10 more takeaways
A2Z Q2 2026 Earnings Call - Revenue Jumps 78% as Chinese Manufacturing Ramps and Backlog Accelerates
A2Z delivered a pivotal second quarter, marked by a 78% sequential revenue surge to $5.9 million and a near-doubling of Smart Cart deliveries to 950 units. The inflection point was driven by the opera...
- Second-quarter revenue surged 78% sequentially to $5.9 million, driven by Smart Cart hardware sales rising to $4.4 million.
- Smart Cart deliveries nearly doubled from Q1, reaching 950 units and bringing the cumulative total delivered to 3,350 units.
- Gross margins expanded dramatically to 42.6% from 4.2% in Q1, reflecting economies of scale and lower production costs from the new Chinese manufacturing facility.
- +7 more takeaways
Spero Therapeutics Q2 2026 Earnings Call - FDA Approval of Utebzi and Pivot to Immunology
Spero Therapeutics has successfully navigated a pivotal transition, securing FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, while simultaneously pivoting its strategic focus ...
- FDA Approval of Utebzi: The FDA approved Utebzi (tebipenem HBr) on June 17, 2026, as the first and only oral carbapenem for complicated urinary tract infections and pyelonephritis. GSK holds exclusive global commercialization rights, with U.S. availability expected in the second half of 2026.
- Strategic Pivot to Immunology: Spero has repositioned its pipeline to focus on immune-mediated diseases, moving away from its previous antibiotic-centric model. This shift is anchored by the new lead asset, SP001.
- In-Licensing of SP001: On July 8, 2026, Spero announced an exclusive worldwide license (excluding Greater China) for SP001 (IBI355) from Innovent Biologics. The deal carries an estimated total contingent value of $1.1 billion.
- +7 more takeaways
Grocery Outlet Q2 2026 Earnings Call - Opportunistic Sales Surge Drives Beat on Top and Bottom Line
Grocery Outlet delivered a second-quarter performance that exceeded management’s internal outlook, driven by a revitalized opportunistic assortment and sharper value communication. Comparable store sa...
- Comparable store sales declined just 30 basis points, marking a 70 basis point sequential improvement from Q1 and beating the company’s outlook of a 1.5%-2% decline.
- Revenue increased 1% year-over-year to $1.19 billion, with traffic growing 1.8% despite a 2.1% decline in average basket size.
- Gross margin expanded to 30.2%, exceeding the 29.8%-30.0% outlook, primarily due to reduced promotional spending and better inventory management.
- +7 more takeaways
Marchex Q2 2026 Earnings Call - Archenia Acquisition Drives Bundled AI Solutions and Revenue Expansion
Marchex closed its acquisition of Archenia on July 1, 2026, marking a strategic pivot from pure analytics to bundled AI-powered customer acquisition solutions. The company is leveraging this integrati...
- Archenia acquisition officially closed on July 1, 2026, combining Marchex’s conversational intelligence with Archenia’s performance-based qualification technology.
- Q2 2026 revenue was $11 million, up from $10.6 million in Q1, driven by new sales and existing customer upsells.
- Management provided three specific examples of successful upsells where bundled AI solutions doubled or significantly increased annualized revenue per customer.
- +9 more takeaways
CVD Equipment Corporation Q2 2026 Earnings Call - Divestiture Strengthens Balance Sheet Amidst Order Weakness
CVD Equipment Corporation completed a strategic pivot in Q2 2026 by selling its SDC business, netting a $13.5 million gain that left the company with $23.5 million in cash and zero long-term debt. Thi...
- CVD Equipment closed the sale of its SDC business on April 1, 2026, generating a $13.5 million net gain that significantly bolstered the company's financial position.
- The company ended the quarter with $23.5 million in cash and cash equivalents, up from $8.7 million at year-end, and holds no long-term debt.
- Revenue from continuing operations fell 43% to approximately $2 million, down from $3.4 million in the prior year quarter, reflecting weaker bookings.
- +9 more takeaways
Kura Oncology Q2 2026 Earnings Call - KOMZIFTI Captures Majority New Patient Starts in Second Quarter
Kura Oncology delivered a standout second quarter, with KOMZIFTI generating $9.1 million in net product revenue and securing majority share of new patient starts in the relapsed/refractory NPM1 mutant...
- KOMZIFTI generated $9.1 million in net product revenue, significantly exceeding initial expectations for its second full quarter on the market.
- The drug captured a majority share of new patient starts in the relapsed/refractory NPM1 mutant AML menin inhibitor market, despite launching after a competitor.
- New patient starts grew 35% quarter-over-quarter, while total prescriptions (TRX) accelerated by 60%, indicating strong repeat prescribing and lack of inventory distortion.
- +7 more takeaways
Energous Wireless Power Solutions Q2 2026 Earnings Call - Revenue Surges 217% as Margin Pressure Signals Strategic Ramp
Energous Wireless Power Solutions delivered a violent upward revision to its revenue trajectory in Q2 2026, posting $3.1 million in sales, a 217% jump year-over-year. The company crossed the $10 milli...
- Revenue for Q2 2026 hit $3.1 million, up 217% from $1 million in Q2 2025, with H1 revenue reaching $6.2 million, a 368% increase.
- The company surpassed a critical milestone, exceeding $10 million in trailing twelve-month revenue for the first time.
- Gross margin compressed to 19% in H2 2026 due to three temporary headwinds: U.S. manufacturing retooling costs, premium sourcing for components amid an AI-driven supply vacuum, and absorbing higher input costs to protect strategic customer relationships.
- +9 more takeaways
Crown Crafts FY2027 Q1 Earnings Call - Margin Expansion and Debt Reduction Offset Soft Demand
Crown Crafts delivered a resilient first quarter for fiscal 2027, posting an 8% increase in net sales to $16.8 million despite a challenging consumer environment marked by high interest rates and infl...
- Net sales increased 8% year-over-year to $16.8 million, driven by better inventory availability rather than a surge in consumer demand.
- Adjusted gross margin expanded significantly, climbing nearly three percentage points to 25.6%, reflecting successful pricing strategies and a shift toward higher-margin products.
- The company returned to profitability, reporting a net income of $2.1 million ($0.19 per share) compared to a net loss of $1.1 million in the prior year period.
- +7 more takeaways